TherapeuticsMD (TXMD) Income from Non-Controlling Interests (2024 - 2026)
TherapeuticsMD's (TXMD) quarterly Income from Non-Controlling Interests came in at $523000.0 in Q2 2026, up 39.1% on a YoY basis from $376000.0 in Q2 2025, and up 1.16% quarter-over-quarter from $517000.0 in Q1 2026.
Powered by 
Analysis
TherapeuticsMD (TXMD) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has reported Income from Non-Controlling Interests for 3 consecutive years, with $523000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Non-Controlling Interests rose 39.1% year-over-year to $523000.0; the trailing twelve-month figure through Jun 2026 stood at $2.1 million (up 50.72% YoY), and the FY2025 full-year result was $1.8 million, up 36.61% from the prior year.
- Income from Non-Controlling Interests rose to $523000.0 in Q2 2026 per TXMD's latest filing, from $517000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $534000.0 in Q3 2025 and bottomed at $275000.0 in Q3 2024.
- Historically, Income from Non-Controlling Interests has averaged $427111.1 across 3 years, with a median of $410000.0 in 2025.
- The widest YoY moves for Income from Non-Controlling Interests: up 94.18% in 2025, down 7.74% in 2025.
- Over 3 years, Income from Non-Controlling Interests stood at $333000.0 in 2024, then jumped by 58.26% to $527000.0 in 2025, then slipped by 0.76% to $523000.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $523000.0, $517000.0, and $527000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 10.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -1.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 39.52 Mn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 523,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 523,000.00 |
| Mar 31, 2026 | 517,000.00 |
| Dec 31, 2025 | 527,000.00 |
| Sep 30, 2025 | 534,000.00 |
| Jun 30, 2025 | 376,000.00 |
| Mar 31, 2025 | 410,000.00 |
| Dec 31, 2024 | 333,000.00 |
| Sep 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 349,000.00 |